RECRUITING

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Official Title

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Quick Facts

Study Start:2025-01-01
Study Completion:2029-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07187063

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * AUA high-risk bladder cancer1
  2. * Received induction BCG or gemcitabine/docetaxel
  3. * Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
  1. * High-risk NMIBC within 3 years
  2. * Prior induction intravesical therapy
  3. * Variant histology
  4. * Concurrent upper tract disease

Contacts and Locations

Study Contact

Linda Topjian
CONTACT
7817448420
Linda.M.Topjian@lahey.org
Colette Osborne
CONTACT
Colette.A.Osborne@lahey.org

Principal Investigator

Matthew B Clements, MD, MS
PRINCIPAL_INVESTIGATOR
Lahey Hospital & Medical Center

Study Locations (Sites)

Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
United States

Collaborators and Investigators

Sponsor: Lahey Clinic

  • Matthew B Clements, MD, MS, PRINCIPAL_INVESTIGATOR, Lahey Hospital & Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-01
Study Completion Date2029-01-01

Study Record Updates

Study Start Date2025-01-01
Study Completion Date2029-01-01

Terms related to this study

Additional Relevant MeSH Terms

  • Non-muscle Invasive Bladder Cancer (NMIBC)